Lee Newman
Concepts (557)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 34 | 2025 | 212 | 13.660 |
Why?
| | Occupational Exposure | 35 | 2025 | 356 | 7.170 |
Why?
| | Farmers | 15 | 2025 | 71 | 7.010 |
Why?
| | Small Business | 14 | 2022 | 51 | 6.920 |
Why?
| | Saccharum | 16 | 2025 | 77 | 6.780 |
Why?
| | Heat Stress Disorders | 12 | 2025 | 84 | 5.200 |
Why?
| | Berylliosis | 37 | 2018 | 204 | 5.140 |
Why?
| | Hot Temperature | 13 | 2025 | 396 | 4.670 |
Why?
| | Beryllium | 31 | 2018 | 163 | 4.380 |
Why?
| | Renal Insufficiency, Chronic | 15 | 2025 | 639 | 3.960 |
Why?
| | Workplace | 26 | 2024 | 268 | 3.440 |
Why?
| | Occupational Injuries | 7 | 2023 | 49 | 3.400 |
Why?
| | Agricultural Workers' Diseases | 6 | 2025 | 29 | 3.340 |
Why?
| | Occupational Diseases | 11 | 2025 | 164 | 3.140 |
Why?
| | Guatemala | 19 | 2025 | 347 | 2.540 |
Why?
| | Health Promotion | 12 | 2024 | 786 | 2.440 |
Why?
| | Agriculture | 7 | 2024 | 94 | 2.240 |
Why?
| | Leadership | 7 | 2025 | 410 | 1.970 |
Why?
| | Kidney | 10 | 2025 | 1491 | 1.830 |
Why?
| | Workers' Compensation | 4 | 2019 | 28 | 1.740 |
Why?
| | Organizational Culture | 6 | 2024 | 159 | 1.630 |
Why?
| | Creatinine | 8 | 2025 | 511 | 1.460 |
Why?
| | Sarcoidosis | 13 | 2012 | 164 | 1.330 |
Why?
| | Safety Management | 6 | 2021 | 130 | 1.250 |
Why?
| | Humans | 151 | 2026 | 145625 | 1.250 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 743 | 1.250 |
Why?
| | Adult | 69 | 2025 | 40821 | 1.240 |
Why?
| | Chronic Disease | 28 | 2025 | 1824 | 1.120 |
Why?
| | Occupational Medicine | 2 | 2025 | 13 | 1.100 |
Why?
| | Population Surveillance | 4 | 2025 | 477 | 1.060 |
Why?
| | Longitudinal Studies | 13 | 2025 | 3005 | 1.040 |
Why?
| | Dehydration | 5 | 2025 | 59 | 1.040 |
Why?
| | Male | 83 | 2025 | 73014 | 1.030 |
Why?
| | Absenteeism | 2 | 2018 | 51 | 1.020 |
Why?
| | Body Temperature | 2 | 2025 | 227 | 1.020 |
Why?
| | Middle Aged | 63 | 2025 | 36359 | 0.970 |
Why?
| | Lymphocytes | 4 | 2018 | 379 | 0.970 |
Why?
| | Heat-Shock Response | 2 | 2025 | 78 | 0.970 |
Why?
| | Health Behavior | 5 | 2022 | 801 | 0.970 |
Why?
| | Biomarkers | 8 | 2024 | 4329 | 0.940 |
Why?
| | Kidney Diseases | 3 | 2025 | 427 | 0.890 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2024 | 76 | 0.890 |
Why?
| | Industry | 4 | 2019 | 43 | 0.850 |
Why?
| | Efficiency | 3 | 2024 | 102 | 0.850 |
Why?
| | Colorado | 19 | 2023 | 4588 | 0.840 |
Why?
| | Inservice Training | 1 | 2025 | 114 | 0.840 |
Why?
| | Body Temperature Regulation | 1 | 2025 | 106 | 0.810 |
Why?
| | Inhalation Exposure | 2 | 2025 | 103 | 0.810 |
Why?
| | Air Pollution | 2 | 2025 | 314 | 0.780 |
Why?
| | Environmental Monitoring | 6 | 2025 | 346 | 0.770 |
Why?
| | Developing Countries | 1 | 2025 | 312 | 0.740 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 36 | 0.730 |
Why?
| | Occupational Stress | 1 | 2023 | 46 | 0.730 |
Why?
| | Air Pollutants | 4 | 2020 | 406 | 0.720 |
Why?
| | Female | 67 | 2025 | 79080 | 0.670 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 861 | 0.650 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 227 | 0.630 |
Why?
| | Neurophysins | 1 | 2020 | 5 | 0.630 |
Why?
| | Arsenic | 1 | 2021 | 66 | 0.620 |
Why?
| | Mexico | 3 | 2025 | 232 | 0.610 |
Why?
| | Anemia | 1 | 2021 | 189 | 0.610 |
Why?
| | Risk Factors | 24 | 2025 | 10840 | 0.610 |
Why?
| | Capacity Building | 1 | 2020 | 61 | 0.610 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 1158 | 0.600 |
Why?
| | Glycopeptides | 1 | 2020 | 48 | 0.600 |
Why?
| | Vasopressins | 1 | 2020 | 60 | 0.600 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 32 | 0.600 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 65 | 0.590 |
Why?
| | Protein Precursors | 1 | 2020 | 127 | 0.590 |
Why?
| | Program Evaluation | 4 | 2025 | 945 | 0.570 |
Why?
| | Particulate Matter | 4 | 2025 | 328 | 0.570 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 5875 | 0.570 |
Why?
| | Presenteeism | 1 | 2018 | 6 | 0.560 |
Why?
| | Young Adult | 15 | 2025 | 14240 | 0.560 |
Why?
| | Smoking | 8 | 2021 | 1478 | 0.550 |
Why?
| | Latin America | 3 | 2025 | 96 | 0.550 |
Why?
| | Cell Proliferation | 5 | 2018 | 2497 | 0.550 |
Why?
| | Veterinarians | 1 | 2018 | 12 | 0.550 |
Why?
| | Mass Screening | 4 | 2025 | 1300 | 0.550 |
Why?
| | Sleep | 2 | 2023 | 896 | 0.530 |
Why?
| | Drug Utilization | 1 | 2018 | 170 | 0.530 |
Why?
| | Accidents, Occupational | 2 | 2015 | 18 | 0.520 |
Why?
| | Body Composition | 1 | 2021 | 686 | 0.520 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2011 | 1148 | 0.520 |
Why?
| | Text Messaging | 1 | 2020 | 187 | 0.510 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.510 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 9 | 0.510 |
Why?
| | Health Personnel | 1 | 2024 | 750 | 0.500 |
Why?
| | Work Performance | 1 | 2017 | 8 | 0.500 |
Why?
| | Mental Health | 1 | 2024 | 771 | 0.500 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.500 |
Why?
| | Professional Role | 1 | 2018 | 171 | 0.500 |
Why?
| | Employment | 3 | 2025 | 180 | 0.490 |
Why?
| | Guidelines as Topic | 1 | 2018 | 267 | 0.490 |
Why?
| | Lymphocyte Activation | 17 | 2014 | 1136 | 0.480 |
Why?
| | Renal Insufficiency | 1 | 2018 | 172 | 0.480 |
Why?
| | Environmental Exposure | 8 | 2013 | 578 | 0.470 |
Why?
| | Federal Government | 1 | 2016 | 23 | 0.470 |
Why?
| | Health Policy | 1 | 2019 | 399 | 0.460 |
Why?
| | Food Industry | 1 | 2015 | 8 | 0.450 |
Why?
| | Hypertension | 2 | 2025 | 1270 | 0.450 |
Why?
| | CpG Islands | 1 | 2015 | 175 | 0.440 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 100 | 0.440 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1223 | 0.440 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 125 | 0.440 |
Why?
| | Safety | 2 | 2015 | 346 | 0.440 |
Why?
| | United States | 17 | 2025 | 16041 | 0.430 |
Why?
| | Climate Change | 4 | 2026 | 184 | 0.420 |
Why?
| | Prevalence | 4 | 2025 | 2852 | 0.410 |
Why?
| | Occupational Health Services | 1 | 2014 | 36 | 0.410 |
Why?
| | Guideline Adherence | 1 | 2018 | 585 | 0.410 |
Why?
| | Chronic Pain | 1 | 2018 | 302 | 0.400 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 32 | 0.400 |
Why?
| | Pulmonary Fibrosis | 3 | 2005 | 395 | 0.390 |
Why?
| | Natural Gas | 4 | 2014 | 25 | 0.390 |
Why?
| | Cancer Survivors | 3 | 2025 | 347 | 0.390 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 13 | 0.380 |
Why?
| | Lung | 12 | 2019 | 4119 | 0.370 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 219 | 0.360 |
Why?
| | Life Style | 1 | 2015 | 495 | 0.350 |
Why?
| | Mycobacterium | 3 | 2009 | 101 | 0.350 |
Why?
| | Influenza, Human | 2 | 2022 | 634 | 0.340 |
Why?
| | Air Pollutants, Occupational | 4 | 2025 | 41 | 0.340 |
Why?
| | Aged | 24 | 2025 | 26251 | 0.330 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 632 | 0.330 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1236 | 0.330 |
Why?
| | Mass Spectrometry | 1 | 2014 | 728 | 0.330 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 55 | 0.320 |
Why?
| | Logistic Models | 7 | 2022 | 2112 | 0.320 |
Why?
| | DNA Methylation | 1 | 2015 | 721 | 0.320 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 88 | 0.310 |
Why?
| | Ferritins | 2 | 2014 | 69 | 0.310 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 169 | 0.310 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 377 | 0.310 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 611 | 0.300 |
Why?
| | Electrolytes | 2 | 2020 | 52 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1370 | 0.290 |
Why?
| | Macrophages | 2 | 2015 | 1530 | 0.290 |
Why?
| | Mental Disorders | 1 | 2018 | 1133 | 0.290 |
Why?
| | Health Status | 3 | 2021 | 822 | 0.280 |
Why?
| | Delivery of Health Care | 1 | 2016 | 942 | 0.280 |
Why?
| | Temperature | 2 | 2023 | 633 | 0.280 |
Why?
| | Data Collection | 1 | 2011 | 647 | 0.280 |
Why?
| | Perception | 3 | 2021 | 372 | 0.280 |
Why?
| | B-Lymphocytes | 1 | 2014 | 884 | 0.280 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1531 | 0.280 |
Why?
| | Sensitivity and Specificity | 8 | 2023 | 1992 | 0.280 |
Why?
| | HLA Antigens | 4 | 2010 | 241 | 0.270 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 211 | 0.270 |
Why?
| | T-Lymphocytes | 3 | 2014 | 2007 | 0.270 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 25 | 0.260 |
Why?
| | Immunization | 3 | 2005 | 375 | 0.260 |
Why?
| | Time Factors | 5 | 2025 | 7079 | 0.260 |
Why?
| | Program Development | 2 | 2020 | 365 | 0.250 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 15 | 0.250 |
Why?
| | Internet | 1 | 2011 | 656 | 0.250 |
Why?
| | Police | 1 | 2007 | 51 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2455 | 0.250 |
Why?
| | Apoptosis | 4 | 2005 | 2436 | 0.250 |
Why?
| | Methamphetamine | 1 | 2007 | 75 | 0.250 |
Why?
| | Wyoming | 2 | 2018 | 27 | 0.240 |
Why?
| | Case-Control Studies | 10 | 2018 | 3633 | 0.240 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 2 | 0.230 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 183 | 0.230 |
Why?
| | Prospective Studies | 5 | 2020 | 8087 | 0.230 |
Why?
| | Plutonium | 1 | 2005 | 4 | 0.230 |
Why?
| | Neopterin | 2 | 2003 | 13 | 0.230 |
Why?
| | Incidence | 3 | 2025 | 2910 | 0.230 |
Why?
| | Chemical Industry | 1 | 2005 | 9 | 0.230 |
Why?
| | Bronchoalveolar Lavage Fluid | 9 | 2009 | 641 | 0.220 |
Why?
| | Organism Hydration Status | 1 | 2025 | 9 | 0.220 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 61 | 0.220 |
Why?
| | Cohort Studies | 6 | 2019 | 6045 | 0.220 |
Why?
| | Antigen Presentation | 4 | 2014 | 209 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1878 | 0.220 |
Why?
| | Disasters | 1 | 2026 | 101 | 0.220 |
Why?
| | Research | 3 | 2018 | 421 | 0.220 |
Why?
| | Disaster Planning | 1 | 2026 | 109 | 0.220 |
Why?
| | Nuclear Warfare | 1 | 2004 | 10 | 0.210 |
Why?
| | Neoplasms | 5 | 2025 | 2944 | 0.210 |
Why?
| | Proteomics | 2 | 2011 | 1202 | 0.210 |
Why?
| | Humidity | 1 | 2024 | 50 | 0.210 |
Why?
| | Pandemics | 3 | 2022 | 1700 | 0.210 |
Why?
| | Cadmium | 2 | 2022 | 68 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1101 | 0.210 |
Why?
| | Research Design | 2 | 2022 | 1139 | 0.200 |
Why?
| | Age of Onset | 1 | 2006 | 557 | 0.200 |
Why?
| | Health Equity | 1 | 2026 | 139 | 0.200 |
Why?
| | Prognosis | 6 | 2020 | 4331 | 0.200 |
Why?
| | Electronic Health Records | 1 | 2011 | 1208 | 0.190 |
Why?
| | Pneumoconiosis | 2 | 2004 | 20 | 0.190 |
Why?
| | Risk Assessment | 5 | 2021 | 3678 | 0.190 |
Why?
| | Vaccination | 1 | 2011 | 1444 | 0.190 |
Why?
| | Inflammation Mediators | 3 | 2014 | 507 | 0.190 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 4 | 0.190 |
Why?
| | Residence Characteristics | 2 | 2018 | 385 | 0.180 |
Why?
| | Ventilation | 2 | 2019 | 44 | 0.180 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 70 | 0.180 |
Why?
| | Metals, Heavy | 1 | 2022 | 31 | 0.180 |
Why?
| | Nephrology | 1 | 2023 | 59 | 0.180 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2002 | 37 | 0.180 |
Why?
| | Immunity, Active | 1 | 2002 | 8 | 0.180 |
Why?
| | Antibodies | 1 | 2024 | 395 | 0.180 |
Why?
| | Crops, Agricultural | 2 | 2019 | 30 | 0.180 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 543 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 365 | 0.180 |
Why?
| | Metals | 2 | 2004 | 137 | 0.180 |
Why?
| | Health Surveys | 2 | 2018 | 511 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 224 | 0.180 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.170 |
Why?
| | Calculi | 1 | 2021 | 15 | 0.170 |
Why?
| | Organizational Innovation | 1 | 2022 | 123 | 0.170 |
Why?
| | Cotinine | 1 | 2021 | 77 | 0.170 |
Why?
| | Medical Oncology | 1 | 2024 | 344 | 0.170 |
Why?
| | Focus Groups | 1 | 2024 | 587 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 399 | 0.170 |
Why?
| | Fibroblast Growth Factors | 1 | 2002 | 187 | 0.170 |
Why?
| | Nickel | 1 | 2021 | 63 | 0.160 |
Why?
| | Policy | 1 | 2021 | 147 | 0.160 |
Why?
| | Beverages | 1 | 2020 | 67 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2011 | 8351 | 0.160 |
Why?
| | Virus Diseases | 1 | 2022 | 219 | 0.160 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1429 | 0.150 |
Why?
| | Noise, Occupational | 1 | 2019 | 9 | 0.150 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 171 | 0.150 |
Why?
| | Kidney Function Tests | 1 | 2020 | 154 | 0.150 |
Why?
| | Sri Lanka | 1 | 2019 | 8 | 0.150 |
Why?
| | Specific Gravity | 1 | 2019 | 13 | 0.150 |
Why?
| | Central America | 1 | 2019 | 28 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 384 | 0.140 |
Why?
| | Nutritional Status | 1 | 2021 | 344 | 0.140 |
Why?
| | Blood Proteins | 2 | 2011 | 239 | 0.140 |
Why?
| | Climate | 1 | 2019 | 79 | 0.140 |
Why?
| | Social Support | 1 | 2023 | 644 | 0.140 |
Why?
| | India | 1 | 2019 | 213 | 0.140 |
Why?
| | Interferon-gamma | 5 | 2015 | 780 | 0.140 |
Why?
| | Unemployment | 1 | 2018 | 43 | 0.140 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 10 | 0.140 |
Why?
| | Headache Disorders | 1 | 2018 | 18 | 0.140 |
Why?
| | Cytokines | 4 | 2014 | 2079 | 0.140 |
Why?
| | Digestive System Diseases | 1 | 2018 | 28 | 0.140 |
Why?
| | Models, Psychological | 1 | 2020 | 290 | 0.140 |
Why?
| | Global Health | 2 | 2016 | 402 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 124 | 0.140 |
Why?
| | Asbestosis | 2 | 2011 | 13 | 0.140 |
Why?
| | Granuloma | 2 | 2014 | 96 | 0.140 |
Why?
| | Urologic Diseases | 1 | 2018 | 42 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 926 | 0.130 |
Why?
| | Allopurinol | 1 | 2018 | 70 | 0.130 |
Why?
| | Reference Standards | 1 | 2018 | 176 | 0.130 |
Why?
| | Educational Status | 1 | 2020 | 466 | 0.130 |
Why?
| | Survivorship | 1 | 2018 | 59 | 0.130 |
Why?
| | Benchmarking | 1 | 2019 | 192 | 0.130 |
Why?
| | Adolescent | 7 | 2021 | 22451 | 0.130 |
Why?
| | Catalase | 2 | 2009 | 133 | 0.130 |
Why?
| | Physical Exertion | 1 | 2019 | 204 | 0.130 |
Why?
| | Body Mass Index | 2 | 2018 | 2446 | 0.130 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 48 | 0.130 |
Why?
| | Fever | 1 | 2019 | 320 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 677 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 567 | 0.130 |
Why?
| | Arthritis | 1 | 2018 | 97 | 0.130 |
Why?
| | Job Satisfaction | 1 | 2020 | 235 | 0.130 |
Why?
| | Awareness | 1 | 2018 | 113 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 97 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 119 | 0.120 |
Why?
| | Self Report | 1 | 2021 | 869 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 178 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1511 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 290 | 0.120 |
Why?
| | Community Health Planning | 1 | 2016 | 38 | 0.120 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.120 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 3 | 0.120 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1500 | 0.120 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 44 | 0.120 |
Why?
| | Hypersensitivity | 2 | 2012 | 253 | 0.120 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 109 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2002 | 843 | 0.110 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 93 | 0.110 |
Why?
| | Linear Models | 1 | 2018 | 847 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1318 | 0.110 |
Why?
| | Population Health | 1 | 2016 | 44 | 0.110 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 137 | 0.110 |
Why?
| | Cell Line | 2 | 2015 | 2809 | 0.110 |
Why?
| | Motivation | 1 | 2020 | 601 | 0.110 |
Why?
| | Mice | 8 | 2019 | 18266 | 0.110 |
Why?
| | Heart Diseases | 1 | 2018 | 341 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1403 | 0.110 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 6 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1125 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 298 | 0.110 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 174 | 0.110 |
Why?
| | Macrophage Activation | 1 | 2015 | 182 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 820 | 0.110 |
Why?
| | Mast Cells | 1 | 1996 | 148 | 0.100 |
Why?
| | Community Health Services | 1 | 2016 | 229 | 0.100 |
Why?
| | Ions | 1 | 2014 | 66 | 0.100 |
Why?
| | Fruit | 1 | 2015 | 144 | 0.100 |
Why?
| | Allergens | 3 | 2006 | 390 | 0.100 |
Why?
| | Disease Progression | 5 | 2011 | 2857 | 0.100 |
Why?
| | Research Personnel | 1 | 2016 | 189 | 0.100 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 143 | 0.100 |
Why?
| | Endotoxins | 2 | 2006 | 215 | 0.100 |
Why?
| | Vegetables | 1 | 2015 | 159 | 0.100 |
Why?
| | Communication | 1 | 2020 | 979 | 0.100 |
Why?
| | Immunologic Memory | 3 | 2005 | 369 | 0.100 |
Why?
| | Community-Based Participatory Research | 2 | 2025 | 172 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1758 | 0.100 |
Why?
| | Health Impact Assessment | 1 | 2013 | 7 | 0.100 |
Why?
| | Genotype | 6 | 2011 | 1866 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2020 | 17291 | 0.090 |
Why?
| | Cell Division | 2 | 2004 | 735 | 0.090 |
Why?
| | Water Supply | 2 | 2016 | 90 | 0.090 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 15 | 0.090 |
Why?
| | Up-Regulation | 2 | 2006 | 840 | 0.090 |
Why?
| | Sex Factors | 1 | 2018 | 2101 | 0.090 |
Why?
| | Hydrocarbons | 1 | 2012 | 29 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2012 | 28 | 0.090 |
Why?
| | Paper | 1 | 2011 | 9 | 0.090 |
Why?
| | Personnel, Hospital | 1 | 2011 | 29 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 389 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 415 | 0.090 |
Why?
| | Vital Capacity | 2 | 2019 | 293 | 0.080 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.080 |
Why?
| | Bacterial Proteins | 2 | 2009 | 976 | 0.080 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 451 | 0.080 |
Why?
| | Liver | 2 | 2018 | 1859 | 0.080 |
Why?
| | Glutamic Acid | 2 | 2003 | 255 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2010 | 3 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1581 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2591 | 0.080 |
Why?
| | Alleles | 4 | 2011 | 900 | 0.080 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 77 | 0.080 |
Why?
| | Mesalamine | 1 | 2009 | 9 | 0.080 |
Why?
| | Sulfasalazine | 1 | 2009 | 22 | 0.080 |
Why?
| | Phenotype | 3 | 2010 | 3186 | 0.080 |
Why?
| | Animals | 10 | 2019 | 38030 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 344 | 0.070 |
Why?
| | Cell Separation | 2 | 2009 | 300 | 0.070 |
Why?
| | Uveitis | 1 | 2010 | 151 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1098 | 0.070 |
Why?
| | Silicosis | 1 | 1989 | 30 | 0.070 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 70 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 676 | 0.070 |
Why?
| | Swimming Pools | 1 | 2007 | 7 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2007 | 7 | 0.070 |
Why?
| | Alcohol Drinking | 1 | 2015 | 847 | 0.060 |
Why?
| | Crime | 1 | 2007 | 58 | 0.060 |
Why?
| | Animal Technicians | 2 | 2006 | 2 | 0.060 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2910 | 0.060 |
Why?
| | Spirometry | 3 | 2019 | 234 | 0.060 |
Why?
| | Water Microbiology | 1 | 2007 | 86 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2006 | 2783 | 0.060 |
Why?
| | Aerosols | 1 | 2007 | 146 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2011 | 541 | 0.060 |
Why?
| | Cells, Cultured | 5 | 2009 | 4112 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2766 | 0.060 |
Why?
| | Biopsy | 3 | 2005 | 1073 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 176 | 0.060 |
Why?
| | Genetic Markers | 2 | 2010 | 337 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 76 | 0.060 |
Why?
| | Gene Dosage | 1 | 2006 | 146 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 610 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 611 | 0.060 |
Why?
| | Risk | 2 | 2007 | 917 | 0.060 |
Why?
| | RNA Precursors | 1 | 2006 | 155 | 0.060 |
Why?
| | Biopsy, Needle | 2 | 2002 | 182 | 0.050 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 76 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 824 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 585 | 0.050 |
Why?
| | Genetic Linkage | 1 | 2005 | 269 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 127 | 0.050 |
Why?
| | Radioisotopes | 1 | 2004 | 37 | 0.050 |
Why?
| | fas Receptor | 1 | 2004 | 91 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 544 | 0.050 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
| | Odds Ratio | 3 | 2014 | 1070 | 0.050 |
Why?
| | Phagocytes | 1 | 2004 | 79 | 0.050 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 58 | 0.050 |
Why?
| | Radiation Dosage | 1 | 2005 | 193 | 0.050 |
Why?
| | CD28 Antigens | 1 | 2003 | 57 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1334 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 511 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2003 | 16 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1553 | 0.050 |
Why?
| | Tuberculosis | 1 | 2006 | 289 | 0.050 |
Why?
| | Animals, Laboratory | 1 | 2003 | 22 | 0.050 |
Why?
| | Public Health | 2 | 2022 | 573 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 861 | 0.050 |
Why?
| | Physiological Phenomena | 1 | 2002 | 3 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2014 | 11744 | 0.050 |
Why?
| | Culture Techniques | 1 | 2002 | 65 | 0.050 |
Why?
| | Contraindications | 1 | 2002 | 88 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 674 | 0.050 |
Why?
| | Exercise | 1 | 2015 | 2206 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2002 | 24 | 0.050 |
Why?
| | Radiography | 2 | 2003 | 856 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.040 |
Why?
| | Genetic Variation | 1 | 2007 | 992 | 0.040 |
Why?
| | Patch Tests | 1 | 2002 | 61 | 0.040 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 88 | 0.040 |
Why?
| | Epitopes | 1 | 2003 | 479 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 423 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2004 | 719 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2006 | 739 | 0.040 |
Why?
| | Nuclear Weapons | 2 | 2011 | 7 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 845 | 0.040 |
Why?
| | Reference Values | 1 | 2002 | 787 | 0.040 |
Why?
| | Equipment Design | 1 | 2002 | 519 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 185 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 634 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2018 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 8 | 0.040 |
Why?
| | ROC Curve | 2 | 2003 | 613 | 0.040 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 14 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 28 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2088 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 107 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2835 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 1033 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 38 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 69 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 700 | 0.030 |
Why?
| | Health | 1 | 2018 | 81 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1709 | 0.030 |
Why?
| | Cities | 1 | 2018 | 140 | 0.030 |
Why?
| | Transcription Factors | 1 | 2006 | 1728 | 0.030 |
Why?
| | Genetic Association Studies | 2 | 2010 | 376 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 79 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1101 | 0.030 |
Why?
| | Quality of Life | 2 | 2012 | 3187 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1030 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2674 | 0.030 |
Why?
| | Haplotypes | 2 | 2010 | 505 | 0.030 |
Why?
| | Fibrosis | 1 | 2000 | 568 | 0.030 |
Why?
| | Uric Acid | 1 | 2018 | 167 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 226 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 122 | 0.030 |
Why?
| | Observer Variation | 1 | 1997 | 355 | 0.030 |
Why?
| | Cost of Illness | 1 | 2018 | 322 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 867 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 495 | 0.030 |
Why?
| | Sanitation | 1 | 2016 | 56 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 290 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 530 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 460 | 0.030 |
Why?
| | Dyspnea | 3 | 2005 | 251 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5397 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 350 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 330 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 196 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 1800 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 92 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 128 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 2064 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 339 | 0.020 |
Why?
| | Universities | 1 | 2016 | 450 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2014 | 67 | 0.020 |
Why?
| | Interleukin-2 | 2 | 2005 | 434 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 154 | 0.020 |
Why?
| | Education, Medical | 1 | 2016 | 273 | 0.020 |
Why?
| | Cleft Palate | 1 | 2014 | 91 | 0.020 |
Why?
| | Mitochondria | 1 | 2019 | 996 | 0.020 |
Why?
| | Bronchiolitis | 1 | 1993 | 87 | 0.020 |
Why?
| | Lung Diseases | 1 | 1999 | 787 | 0.020 |
Why?
| | Politics | 1 | 2013 | 89 | 0.020 |
Why?
| | Maternal Exposure | 1 | 2014 | 189 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 40 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 70 | 0.020 |
Why?
| | Pneumonia | 1 | 1997 | 633 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 22 | 0.020 |
Why?
| | Pregnancy | 2 | 2014 | 7217 | 0.020 |
Why?
| | Finland | 1 | 2011 | 72 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 345 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 277 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1720 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 16 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 84 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2915 | 0.020 |
Why?
| | Japan | 1 | 2010 | 149 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 49 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 52 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 389 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 52 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 161 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 376 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 58 | 0.020 |
Why?
| | Demography | 1 | 2009 | 274 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 2097 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 11 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4565 | 0.020 |
Why?
| | Codon | 1 | 2007 | 92 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 2218 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 8 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 6021 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1102 | 0.010 |
Why?
| | Placebos | 1 | 2006 | 190 | 0.010 |
Why?
| | Disinfection | 1 | 2007 | 131 | 0.010 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 366 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 337 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2007 | 494 | 0.010 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 920 | 0.010 |
Why?
| | Eye | 1 | 2006 | 112 | 0.010 |
Why?
| | Decision Making | 1 | 2013 | 987 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1160 | 0.010 |
Why?
| | Caspase 8 | 1 | 2005 | 48 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2005 | 64 | 0.010 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 81 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2005 | 166 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2005 | 62 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 376 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 233 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 505 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 542 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 56 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2011 | 927 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 3 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 77 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 57 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1526 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 325 | 0.010 |
Why?
| | Geography | 1 | 2003 | 186 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 94 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 277 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 491 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 306 | 0.010 |
Why?
| | Th1 Cells | 1 | 2002 | 138 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 6449 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 138 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 47 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1498 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 21 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 252 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1367 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1041 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 382 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 360 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 516 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 10 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 27 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 386 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 386 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 259 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 667 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 950 | 0.010 |
Why?
| | Skin | 1 | 2002 | 701 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1571 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1566 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 10 | 0.010 |
Why?
| | Cough | 1 | 1993 | 123 | 0.010 |
Why?
| | Bronchoscopy | 1 | 1993 | 227 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 6050 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 115 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|